Article Information
History
- November 23, 2020.
Article Versions
- You are currently viewing Version 1 of this article (November 23, 2020 - 09:18).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
- 2Department of Pharmacology, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
- 3Centre for PanorOmic Sciences-Genomics and Bioinformatics Cores, The University of Hong Kong, Hong Kong
- 4Department of Health Service Management, School of Public Health, Tianjin Medical University, Tianjin, China
- 5Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
- ↵*Correspondence should be addressed to Mulin Jun Li (e-mail: mulinli{at}connect.hku.hk)
Posted November 23, 2020.
Coagulation factors and COVID-19 severity: Mendelian randomization analyses and supporting evidence
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos